Adaptive Radiation Treatment for Head and Neck Cancer
Status:
Active, not recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This Phase III trial aims to:
Explore the impact of pre-treatment information and radiation dose redistribution on
locoregional control in patients with locally advanced SCCHN.
The dose to the primary tumor with margins, based upon PET and CT information, will be
inhomogeneously increased to a tumor dose between 70 and 84 Gy with decreasing dose towards
the edges of the irradiated area.
To determine the toxicity of combined modality treatment (cisplatin) with standard dose
distribution versus combined modality treatment (cisplatin) with adaptive inhomogeneous
radiation dose distribution.
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborators:
European Union Gustave Roussy, Cancer Campus, Grand Paris Institut Catala de Salut Karolinska Institutet Maastricht Radiation Oncology The Christie NHS Foundation Trust UMC Utrecht